Exploring the pathogenetic mechanisms underlying Parkinson's disease in medaka fish

Journal of Parkinson's Disease

Volumn 4, Issue 2, 2014, Pages 301-310

  Matsui, Hideaki ^a   Uemura, Norihito ^b   Yamakado, Hodaka ^b   Takeda, Shunichi ^b   Takahashi, Ryosuke ^b  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

dopaminergic neurons; medaka fish; model animal; Parkinson's disease

Indexed keywords

OXIDOPAMINE; PROTEASOME; TYROSINE 3 MONOOXYGENASE; NEUROTOXIN;

AUTOPHAGY; CELL AGGREGATION; CEREBROSPINAL FLUID; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM STRESS; GENE; HOMOZYGOSITY; IMMUNOREACTIVITY; NONHUMAN; ORYZIAS LATIPES; OXIDATIVE STRESS; PARKIN GENE; PARKINSON DISEASE; PATHOGENESIS; PINK1 GENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; REVIEW; SEQUENCE HOMOLOGY; SUBSTANTIA NIGRA; TELENCEPHALON; UBIQUITINATION; ZEBRA FISH; ANIMAL; BRAIN; CHEMICALLY INDUCED; DISEASE MODEL; GENETICS; ORYZIAS; PARKINSONISM; PATHOLOGY; TOXICITY; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BRAIN; DISEASE MODELS, ANIMAL; NEUROTOXINS; ORYZIAS; PARKINSON DISEASE; PARKINSONIAN DISORDERS;

EID: 84901835532     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-130289     Document Type: Review

References (75)

1. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, &Mandel J (2011) Epidemiology and etiology of Parkinson's disease: A review of the evidence. Eur J Epidemiol, 26, S1-S58.
2. Lim SY, & Lang AE (2010) The nonmotor symptoms of Parkinson's disease-an overview. Mov Disord, 25(Suppl 1), S123-S130.
3. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, & Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA, 95, 6469-6473.
4. Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, Landon M,&Mayer RJ (1988) Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J Pathol, 155, 9-15.
5. Manetto V, Perry G, Tabaton M, Mulvihill P, Fried VA, Smith HT, Gambetti P, & Autilio-Gambetti L (1988) Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative diseases. Proc Natl Acad Sci USA, 85, 4501-4505.
6. Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, & Ihara Y (1988) Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol, 75, 345-353.
7. Braak H, & Del Tredici K (2008) Nervous system pathology in sporadic Parkinson disease. Neurology, 70, 1916-1925.
8. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, & Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
9. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, & Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605-608.
10. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, & Gwinn-Hardy K (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
11. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonźalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, & Wood NW (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 304, 1158-1160.
12. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, & Heutink P (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299, 256-259.
13. Di Fonzo A, Roh́e CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M,Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, & Bonifati V; Italian Parkinson Genetics Network (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet, 365, 412-415.
14. Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, HulihanMM,Cobb SA,Wu RM, Lu CS, Lahoz C, Wszolek ZK, & Farrer MJ (2005) Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics, 6, 171-177.
15. Ramirez A, Heimbach A, Gr̈undemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF,Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI, & Kubisch C (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet, 38, 1184-1191.
16. SatakeW, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T,Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, & Toda T (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet, 41, 1303-1307.
17. Siḿon-Śanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Kr̈uger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X,WoodNW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, & Gasser T (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet, 41, 1308-1312.
18. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, D̈urr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M,Tan EK,Tayebi N, Toda T, Troiano AR, Tsuji S,Wittstock M,Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y,&Ziegler SG (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med, 361, 1651-1661.
19. Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, Bressman S, Deligtisch A, Marras C, Lyons KE, Bhudhikanok GS, Roucoux DF, Meng C, Abbott RD, & Langston JW (2009) Occupation and risk of parkinsonism. A multicenter case-control study. Arch Neurol, 66, 1106-1113.
20. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, & Langston JW (2011) Rotenone, paraquat and Parkinson's disease. Environ Health Perspect, 119, 866-872.
21. Costello S, Cockburn M, Bronstein J, Zhang X, & Ritz B (2009) Parkinson's disease and residential exposure to maneb and paraquat from agri-cultural applications in the central valley of California. Am J Epidemiol, 169, 919-926.
22. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, & Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci, 3, 1301-1306.
23. TieuK(2011)Aguide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med, 1, a009316.
24. Kitada T, Tong Y, Gautier CA, & Shen J (2009) Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. J Neurochem, 111, 696-702.
25. Clark IE, DodsonMW, Jiang C, Cao JH, Huh JR, Seol JH,Yoo SJ, HayBA,&GuoM(2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature, 441, 1162-1166.
26. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, & Chung J (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature, 441, 1157-1161.
27. Wittbrodt J, Shima A, & Schartl M (2002) Medaka-a model organism from the far East. Nat Rev Genet, 3, 53-64.
28. Kasahara M, Naruse K, Sasaki S, NakataniY, QuW, Ahsan B, Yamada T, Nagayasu Y, Doi K, Kasai Y, Jindo T, Kobayashi D, Shimada A, Toyoda A, Kuroki Y, Fujiyama A, Sasaki T, Shimizu A, Asakawa S, Shimizu N, Hashimoto S,Yang J, Lee Y, Matsushima K, Sugano S, Sakaizumi M, Narita T, Ohishi K, Haga S, Ohta F, Nomoto H, Nogata K, Morishita T, Endo T, Shin-I T, Takeda H, Morishita S, & Kohara Y (2007) The medaka draft genome and insights into vertebrate genome evolution. Nature, 447, 714-719.
29. Kinoshita M, Murata K, Naruse K, & Tanaka M (2009) Medaka: Biology, management and experimental protocols. Wiley-Blackwell, Ames, IA.
30. Takeda H, & Shimada A (2010) The art of medakagenetics and genomics: What makes them so unique? Annu Rev Genet, 44, 217-241.
31. Flinn L, Bretaud S, Lo C, InghamPW,&Bandmann O (2008) Zebrafish as a new animal model for movement disorders. J Neurochem, 106, 1991-1997.
32. Hasegawa S, Maruyama K, Takenaka H, Furukawa T, & Saga T (2009) A medaka model of cancer allowing direct observation of transplanted tumor cells in vivo at a cellular-level resolution. Proc Natl Acad Sci USA, 106, 13832-13837.
33. Ingham PW (2009) The power of the zebrafish for disease analysis. Hum Mol Genet, 18, R107-R112.
34. Schweitzer J, L̈ohr H, Filippi A, & Driever W (2012) Dopaminergic and noradrenergic circuit development in zebrafish. Dev Neurobiol, 72, 256-268.
35. Kaslin J, & Panula P (2001) Comparative anatomy of the histaminergic and other aminergic systems in zebrafish (Danio rerio). J Comp Neurol, 440, 342-377.
36. Yamamoto K, Ruuskanen JO, Wullimann MF, & Vernier P (2010) Two tyrosine hydroxylase genes in vertebrates new dopaminergic territories revealed in the zebrafish brain. Mol Cell Neurosci, 43, 394-402.
37. Ma PM (1997) Catecholaminergic systems in the zebrafish. III. Organization and projection pattern of medullary dopaminergic and noradrenergic neurons. J Comp Neurol, 381, 411-427.
38. Ma PM (2003) Catecholaminergic systems in the zebrafish. IV. Organization and projection pattern of dopaminergic neurons in the diencephalon. J Comp Neurol, 460, 13-37.
39. Rink E, & Wullimann MF (2002) Development of the catecholaminergic system in the early zebrafish brain: An immunohistochemical study. Brain Res Dev Brain Res, 137, 89-100.
40. Sallinen V, Torkko V, Sundvik M, Reenil̈a I, Khrustalyov D, Kaslin J, & Panula P (2009) MPTP and MPP+ target specific aminergic cell populations in larval zebrafish. J Neurochem, 108, 719-731.
41. Matsui H, Taniguchi Y, Inoue H, Uemura K, Takeda S, & Takahashi R (2009) A chemical neurotoxin, MPTP induces Parkinson's disease like phenotype, movement disorders and persistent loss of dopamine neurons in medaka fish. Neurosci Res, 65, 263-271.
42. Matsui H, Gavinio R, & Takahashi R (2012) Medaka fish Parkinson's disease model. Exp Neurobiol, 21, 94-100.
43. Langston JW, Ballard P, Tetrud JW, & Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidineanalog synthesis. Science, 219, 979-980.
44. Gerlach M, Riederer P, Przuntek H, & Youdim MB (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol, 208, 273-286.
45. Bretaud S, Lee S, & Guo S (2004) Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease. Neurotoxicol Teratol, 26, 857-864.
46. McKinley ET, Baranowski TC, Blavo DO, Cato C, Doan TN, & Rubinstein AL (2005) Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons. Brain Res Mol Brain Res, 141, 128-137.
47. Lam CS, Korzh V, & Strahle U (2005) Zebrafish embryos are susceptible to the dopaminergic neurotoxin MPTP. Eur J Neurosci, 21, 1758-1762.
48. Sachs C, & Jonsson G (1975) Mechanisms of action of 6-hydroxydopamine. Biochem Pharmacol, 24, 1-8.
49. Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central dopamine neurons. Eur J Pharmacol, 5, 107-110.
50. Zhang ZJ, Cheang LC, Wang MW, Li GH, Chu IK, Lin ZX, & Lee SM (2012) Ethanolic extract of fructus Alpinia oxyphylla protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish. Cell Mol Neurobiol, 32, 27-40.
51. Anichtchik OV, Kaslin J, Peitsaro N, Scheinin M, & Panula P (2004) Neurochemical and behavioural changes in zebrafish Danio rerio after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. J Neurochem, 88, 443-453.
52. Bedford L, Hay D, Devoy A, Paine S, Powe DG, Seth R, Gray T, Topham I, Fone K, Rezvani N, Mee M, Soane T, Layfield R, Sheppard PW, Ebendal T, Usoskin D, Lowe J, & Mayer RJ (2008) Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci, 28, 8189-8198.
53. Ahmed I, Liang Y, Schools S, Dawson VL, Dawson TM, & Savitt JM (2012) Development and characterization of a new Parkinson's disease model resulting from impaired autophagy. J Neurosci, 32, 16503-16509.
54. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, & Takahashi R (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell, 105, 891-902.
55. Wang HQ, Imai Y, Inoue H, Kataoka A, Iita S, Nukina N, & Takahashi R (2008) Pael-R transgenic mice crossed with parkin deficient mice displayed progressive and selective catecholaminergic neuronal loss. J Neurochem, 107, 171-185.
56. Matsui H, Ito H, TaniguchiY, Inoue H, Takeda S,&Takahashi R (2010) Proteasome inhibition in medaka brain induces the features of Parkinson's disease. J Neurochem, 115, 178-187.
57. Matsui H, Ito H, TaniguchiY, Takeda S,&TakahashiR(2010) Ammonium chloride and tunicamycin are novel toxins for dopaminergic neurons and induce Parkinson's disease-like phenotypes in medaka fish. J Neurochem, 115, 1150-1160.
58. Taniguchi Y, Takeda S, Furutani-Seiki M, Kamei Y, Todo T, Sasado T, Deguchi T, Kondoh H, Mudde J, Yamazoe M, Hidaka M, Mitani H, Toyoda A, Sakaki Y, Plasterk RH, & Cuppen E (2006) Generation of medaka gene knockout models by target-selected mutagenesis. Genome Biol, 7, R116.
59. Matsui H, Taniguchi Y, Inoue H, Kobayashi Y, Sakaki Y, Toyoda A, Uemura K, Kobayashi D, Takeda S, & Takahashi R (2010) Loss of PINK1 in medaka fish (Oryzias latipes) causes late-onset decrease in spontaneous movement. Neurosci Res, 66, 151-161.
60. Matsui H, Gavinio R, Asano T, Uemura N, Ito H, TaniguchiY, KobayashiY, MakiT, Shen J,Takeda S, Uemura K,Yamakado H,&Takahashi R (2013) PINK1 and Parkin complementarily protect dopaminergic neurons in vertebrates. Hum Mol Genet, 22, 2423-2434.
61. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, Cookson MR, & Youle RJ (2010) PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol, 8, e1000298.
62. Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, Kim J, May J, Tocilescu MA, Liu W, Ko HS, Magrańe J, Moore DJ, Dawson VL, Grailhe R, Dawson TM, Li C, Tieu K, & Przedborski S (2010) PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci USA, 107, 378-383.
63. Okatsu K, Oka T, Iguchi M, Imamura K, Kosako H, Tani N, Kimura M, Go E, Koyano F, Funayama M, Shiba-Fukushima K, Sato S, Shimizu H, Fukunaga Y, Taniguchi H, Komatsu M, Hattori N, Mihara K, Tanaka K, & Matsuda N (2012) PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. Nat Commun, 3, 1016.
64. Geisler S, Holmstr̈om KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, & SpringerW(2010) PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol, 12, 119-131.
65. Flinn LJ, Keatinge M, Bretaud S, Mortiboys H, Matsui H, De Felice E,Woodroof HI, Brown L, McTighe A, Soellner R, Allen CE, Heath PR, Milo M, MuqitMM,Reichert AS,K̈oster RW, Ingham PW,&Bandmann O (2013) TigarB causes mitochondrial dysfunction and neuronal loss in PINK1 deficiency. Ann Neurol, doi: 10.1002/ana.23999.
66. Bedell VM, Wang Y, Campbell JM, Poshusta TL, Starker CG, Krug RG 2nd, TanW, Penheiter SG, Ma AC, Leung AY, Fahrenkrug SC, Carlson DF, Voytas DF, Clark KJ, Essner JJ, & Ekker SC (2012) In vivo genome editing using a highefficiency TALEN system. Nature, 491, 114-118.
67. Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, PetersonRT,Yeh JR,&Joung JK (2013) Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol, 31, 227-229.
68. DoyonY,McCammonJM,Miller JC, Faraji F, Ngo C, Katibah GE, Amora R, Hocking TD, Zhang L, Rebar EJ, Gregory PD, Urnov FD, & Amacher SL (2008) Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol, 26, 702-708.
69. Ansai S, Inohaya K, Yoshiura Y, Schartl M, Uemura N, Takahashi R, & Kinoshita M (2013) Design, evaluation, and screening methods for efficient targeted mutagenesis with transcription activator-like effector nucleases in medaka. Dev Growth Differ, doi: 10.1111/dgd.12104.
70. Ansai S, Sakuma T, Yamamoto T, Ariga H, Uemura N, Takahashi R,&KinoshitaM(2013) Efficient targeted mutagenesis in medaka using custom-designed transcription activator-like effector nucleases. Genetics, 193, 739-749.
71. Matsui H, Sato F, Sato S, Koike M, Taruno Y, Saiki S, Funayama M, Ito H, Taniguchi Y, Uemura N, Toyoda A, Sakaki Y, Takeda S, Uchiyama Y, Hattori N, & Takahashi R (2013)ATP13A2 deficiency induces a decrease in cathepsinD activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons. FEBS Lett, 587, 1316-1325.
72. Palmer DN, Fearnley IM, Walker JE, Hall NA, Lake BD, Wolfe LS, Haltia M, Martinus RD, & Jolly RD (1992) Mitochondrial ATP synthase subunit c storage in the ceroidlipofuscinoses (Batten disease). Am J Med Genet, 42, 561-567.
73. Tsiakas K, Steinfeld R, Storch S, Ezaki J, Lukacs Z, Kominami E, Kohlscḧutter A, Ullrich K, & Braulke T (2004) Mutation of the glycosylated asparagine residue 286 in human CLN2 protein results in loss of enzymatic activity. Glycobiology, 14, 1C-5C.
74. Tyynel̈a J, Palmer DN, Baumann M, & Haltia M (1993) Storage of saposins A and D in infantile neuronal ceroidlipofuscinosis. FEBS Lett, 330, 8-12.
75. KoikeM, Nakanishi H, Saftig P, Ezaki J, Isahara K, OhsawaY, Schulz-SchaefferW,Watanabe T,Waguri S, Kametaka S, Shibata M, Yamamoto K, Kominami E, Peters C, von Figura K, & Uchiyama Y (2000) Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J Neurosci, 20, 6898-6906.